GVR Report cover Novel Drug Delivery Systems In Cancer Therapy Market Size, Share & Trends Report

Novel Drug Delivery Systems In Cancer Therapy Market Size, Share & Trends Analysis Report By Product (Nanoparticles and Embolization Particles), By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-2-68038-267-9
  • Number of Report Pages: 100
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2022
  • Forecast Period: 2024 - 2030 
  • Industry: Healthcare

Market Size & Trends

The global novel drug delivery systems in cancer therapy market size was valued at USD 16.79 billion in 2023 and is projected to grow at a CAGR of 7.5% from 2024 to 2030. The advent of targeted therapies, precision medicine, and personalized treatment approaches, as well as the growing adoption of minimally invasive procedures are propelling market growth worldwide. Moreover, demand for novel drug development is driven by the need for effective treatment options that enhance patient outcomes while minimizing side effects associated with traditional therapies.

Novel Drug Delivery Systems In Cancer Therapy Market Size by Product, 2020 - 2030 (USD Billion)

Technological advancements in drug delivery technologies, particularly the development of nanoparticles and targeted the rapies, are significantly enhancing the efficacy of cancer treatments. These advancements allow for precise delivery of therapeutic agents to cancer cells while sparing healthy tissues, thus improving the overall therapeutic index. Furthermore, research funding and investment from both public and private sectors are facilitating research and development activities aimed at creating more effective cancer therapies.

Awareness and acceptance of alternative therapies are also driving market growth. Growing awareness among healthcare professionals and patients regarding the benefits of novel drug delivery systems is leading to a shift towards personalized medicine, where treatments are tailored to individual patient needs. This increased demand for advanced drug delivery solutions is further fueled by favorable reimbursement policies in developed countries, which encourage healthcare providers to adopt novel drug delivery systems.

The competitive landscape of the novel drug delivery systems (NDDS) market in cancer therapy is characterized by ongoing research and development efforts by key players, which include investments in new product launches and collaborations. The dynamic nature of the market, influenced by regulatory approvals and technological advancements, continues to shape its growth trajectory. For instance, in July 2024, Bristol Myers Squibb received European Medicines Agency validation of its application for Opdivo plus Yervoy as a first-line treatment for unresectable or advanced hepatocellular carcinoma, based on Phase 3 CheckMate -9DW trial results. As the market evolves, it is expected that new opportunities will emerge for the development of novel drug delivery systems, driven by the increasing need for customized solutions for individual patients.

Product Insights

Nanoparticles accounted for the largest market revenue share of 86.4% in 2023, driven by their ability to enhance drug efficacy and minimize side effects. Nanoparticles enable targeted delivery, improving drug stability and bioavailability, and reducing toxicity to healthy tissues. Advancements in nanotechnology and increasing investments in research and development propel this segment, making it a crucial component in cancer therapy evolution.

Novel Drug Delivery Systems In Cancer Therapy Market Share by Product, 2023 (%)

Embolization particles projected to grow at the fastest CAGR of 10.7% over the forecast period. The growth of the embolization particles segment is driven by the increasing incidence of liver and renal cancers, necessitating effective treatment options. These particles enable targeted delivery of therapeutic agents, promoting localized treatment while minimizing systemic exposure and side effects. Technological advancements in particle formulations and delivery methods further stimulate market growth by improving treatment efficacy and patient outcomes.

Regional Insights

North America novel drug delivery systems in cancer therapy market dominated the global novel drug delivery systems in cancer therapy market in 2023 with 43.4% of the total revenue share. Market growth in the region is fueled by the presence of multiple manufacturers and funding for research into new treatment methods. Several regulatory approvals are currently pending for the introduction of novel medications in the region, utilizing innovative drug delivery systems. This development is expected to fuel market expansion and further solidify North America’s position as a hub for cutting-edge healthcare solutions.

Novel Drug Delivery Systems In Cancer Therapy Market Trends, by Region, 2024 - 2030

U.S. Novel Drug Delivery Systems In Cancer Therapy Market Trends

The novel drug delivery systems in cancer therapy market in the U.S. dominated the North America novel drug delivery systems in cancer therapy market with a share of 81.7% in 2023. In response to the growing cancer patient population, the government is prioritizing healthcare infrastructure development, creating beneficial regulations to increase access to advanced medications and enhance patient care. Novel drug delivery systems have a positive impact on cancer treatment, driving innovation in the sector.

Europe Novel Drug Delivery Systems In Cancer Therapy Market Trends

Europe novel drug delivery systems in cancer therapy market was identified as a lucrative region in 2023. The healthcare sector in Europe has advanced, leading to increased government funding towards the industry and consequently driving the need for advancements in drug delivery technologies for cancer treatment. Technological advancements and the growing acceptance of personalized medicine are driving significant growth in Europe. Cooperative research initiatives and advantageous payment policies play a role in boosting market growth.

The novel drug delivery systems in cancer therapy market in the UK is expected to grow rapidly in the coming years due to the UK government is allocating significant funds towards crucial healthcare providers such as the National Health Service. Partnering with these institutions accelerates research processes that provide improved options for medical professionals in drug delivery therapeutics. These efforts have driven innovation, ultimately helping patients in the nation.

Asia Pacific Novel Drug Delivery Systems In Cancer Therapy Market Trends

Asia Pacific novel drug delivery systems in cancer therapy market is anticipated to witness the fastest growth of 9.4% over the forecast period, owing to increasing number of patients with chronic illnesses is expected to drive market expansion. In addition, the novel drug delivery systems market in this region is anticipated to grow due to the growing focus on healthcare, rising investment in R&D activities, and the growing demand for minimally invasive procedures, as well as the increasing availability of modern drug delivery systems.

The novel drug delivery systems in cancer therapy market in India is expected to grow rapidly in the coming years due to the increasing incidences of cancer, the market for appropriate medicines is on the brink of increasing. Along with it, due to increasing investment in health services’ improvement by the government of India, the chances to get better treatment has arisen. Pharmaceutical sector advancement is working to enhance selection of which medications are suitable for patients, to open possibilities to participants in the competitor’s realm.

Key Novel Drug Delivery Systems In Cancer Therapy Company Insights

Some key companies in novel drug delivery systems in cancer therapy market include Bristol-Myers Squibb Company (Celgene Corporation); Teva Pharmaceutical Industries Ltd; Johnson & Johnson Services, Inc.; Galen Limited; and others. Manufacturers are prioritizing expanding their customer base in order to gain a competitive advantage in the market. Hence, major stakeholders are implementing multiple strategic actions, such as merging with other companies and forming partnerships with big corporations.

  • Teva Pharmaceutical Industries Ltd is a generics and specialty pharmaceutical company, developing and marketing medications for various conditions, including CNS, cancer, respiratory, dermatology, and women’s health. The company’s portfolio includes a range of generic products in various forms, including capsules, tablets, and injectables.

  • Merrimack Pharmaceuticals is a biopharmaceutical company specializing in developing and commercializing targeted cancer therapies in combination with companion diagnostics. The company’s focus is on delivering innovative treatments to patients in the U.S. through its comprehensive pipeline of products.

Key Novel Drug Delivery Systems In Cancer Therapy Companies:

The following are the leading companies in the novel drug delivery systems in cancer therapy market. These companies collectively hold the largest market share and dictate industry trends.

  • Bristol-Myers Squibb Company (Celgene Corporation)
  • Teva Pharmaceutical Industries Ltd
  • Johnson & Johnson Services, Inc.
  • Galen Limited
  • Shire (Takeda Pharmaceutical Company Limited)
  • Samyang Holdings Corporation
  • Merrimack Pharmaceuticals
  • Spectrum Pharmaceuticals, Inc.

Recent Developments

  • In June 2024, Bristol-Myers Squibb Company received FDA accelerated approval for KRAZATI (adagrasib) in combination with cetuximab, a targeted treatment for KRASG12C-mutated CRC patients who had undergone prior chemotherapy, based on ORR and DOR results.

  • In January 2024, Johnson & Johnson acquired Ambrx Biopharma, a clinical-stage biopharmaceutical company, in a cash merger deal valued at approximately USD 2.0 billion, with estimated cash on hand deducted.

Novel Drug Delivery Systems In Cancer Therapy Market Report Scope

Report Attribute

Details

Market size value in 2024

USD 17.74 billion

Revenue forecast in 2030

USD 27.36 billion

Growth rate

CAGR of 7.5% from 2024 to 2030

Base year for estimation

2023

Historical data

2018 - 2022

Forecast period

2024 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2024 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, region

Regional scope

North America, Europe, Asia Pacific, Latin America, MEA

Country scope

U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, Japan, China, India, Australia, South Korea, Thailand, Brazil, Argentina, South Africa, Saudi Arabia, UAE, Kuwait

Key companies profiled

Bristol-Myers Squibb Company (Celgene Corporation); Teva Pharmaceutical Industries Ltd; Johnson & Johnson Services, Inc.; Galen Limited; Shire (Takeda Pharmaceutical Company Limited); Samyang Holdings Corporation; Merrimack Pharmaceuticals; Spectrum Pharmaceuticals, Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Novel Drug Delivery Systems In Cancer Therapy Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global novel drug delivery systems in cancer therapy market report based on product, and region.

Global Novel Drug Delivery Systems In Cancer Therapy Market Report Segmentation

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Nanoparticles

      • Liposomes

      • Polymers

      • Micelles

      • Other Nanoparticles

    • Embolization Particles

      • PVA Particles

      • Drug Eluting Beads

      • Liquid Emboli

      • Other Embolization Particles

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

pdf icn

GET A FREE SAMPLE

arrow icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.